Flagship explainer
What drives BioMarin Pharmaceutical Inc’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $349M | FY2025 |
| |
| Income before tax | $482M | FY2025 |
|
| Operating income | $409M | FY2025 |
|
| $3.2B | FY2025 |
| |
| Ending assets | $7.6B | FY2025 |
|
| Beginning assets | $7.0B | FY2024 |
|
| $6.1B | FY2025 |
| |
| $5.7B | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001048477-26-000004